APA (7th ed.) Citation

Pollack, C. V., Reilly, P. A., Bernstein, R., Dubiel, R., Eikelboom, J., Glund, S., . . . Weitz, J. I. (2015). Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thrombosis and haemostasis, 114(1), . https://doi.org/10.1160/TH15-03-0192

Chicago Style (17th ed.) Citation

Pollack, Charles V., et al. "Design and Rationale for RE-VERSE AD: A Phase 3 Study of Idarucizumab, a Specific Reversal Agent for Dabigatran." Thrombosis and Haemostasis 114, no. 1 (2015). https://doi.org/10.1160/TH15-03-0192.

MLA (9th ed.) Citation

Pollack, Charles V., et al. "Design and Rationale for RE-VERSE AD: A Phase 3 Study of Idarucizumab, a Specific Reversal Agent for Dabigatran." Thrombosis and Haemostasis, vol. 114, no. 1, 2015, https://doi.org/10.1160/TH15-03-0192.